OBJECTIVES This study sought to analyze medical therapy data from the CHAMPION (CardioMEMS Heart Sensor Allows
to include guidelines on how to treat elevated PA pressures to achieve protocol-defined target filling pressure ranges with titration of diuretics and vasodilators (7) . This study compared HF hospitalization rates in patients whose therapy was guided by PA pressures (active monitoring group) with patients whose uploaded PA pressures were not available to the clinicians. In this "blind therapy group," investigators adjusted therapy according to usual clinical information. In CHAMPION, PA pressure-guided HF management was associated with a 28% reduction in HF hospitalization rates after 6 months and 37% after an average follow-up of 15 months relative to management guided by clinical assessment alone (8) . 
METHODS
STUDY DESIGN. The study design and main results of the CHAMPION trial have been previously published in detail (7, 8) . Briefly, from 64 U.S. study sites the trial enrolled 550 New York Heart Association functional class III patients who had been hospitalized for HF in the previous year. Patients were enrolled regardless of LVEF or HF etiology and were required to already be taking all appropriate guidelinedirected medical and device therapies (GDMT) (9) .
The CHAMPION trial was a randomized, controlled, single-blind study with all patients undergoing right heart catheterization and implantation of the wireless hemodynamic monitoring system (CardioMEMS HF System, St. Jude Medical, Inc., Atlanta, Georgia) (10) (11) (12) . For all patients, physicians had access to baseline hemodynamic information from the right heart catheterization. After device implantation, patients were randomized 1:1 to the active monitoring group or to the blind therapy group. All patients in both groups were instructed to transmit daily PA pressure readings from home. Real-time PA pressure information from home monitoring was available to physicians only for patients randomized to the active monitoring group. The primary endpoint for the CHAMPION trial was HF hospitalization rates, which were evaluated at 6 months of follow-up. All hospitalizations and deaths were adjudicated by a clinical events committee blinded to study group assignment. hydralazine, loop diuretics, and daily and as-needed thiazide diuretics at baseline and at 6 months were evaluated (13) . Differences between groups were analyzed using the Fisher exact test.
Outpatient medication changes were tracked during the 6 months of follow-up, including whether the dose was increased or decreased, and were compared between groups using the Wilcoxon rank sum test.
The total daily doses for each HF drug therapy class were also calculated at baseline and after 6 months, converting to equivalents for enalapril, carvedilol, AA spironolactone, furosemide, and metolazone. Conversion details are provided in Online Tables 1 and 2 .
Estimates for the frequency of medication changes, including dose increases or decreases, occurring during the 6 month follow-up period, were also The PA pressure treatment guidelines for the CHAMPION trial used a treatment algorithm in response to patient hemodynamic trend data. The low PA pressure and elevated PA pressure algorithms implemented change protocols for diuretic and/or vasodilator therapies to achieve hemodynamic stabilization. In the presence of normal PA pressures, continuation of existing patient treatment regimens with consideration for further uptitration of guideline-directed medical therapy was recommended.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; CHAMPION ¼ CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in Class III Heart Failure; IV ¼ intravenous; PA ¼ pulmonary artery.
related to baseline PA diastolic pressure for the randomized groups using the Poisson regression methodology (14 there were significant increases in the total daily loop diuretic dose compared with baseline for both treatment groups. For patients on therapy at baseline and at 6 months of follow-up, the increases in furosemide-equivalent dose in the active monitoring group was 25.9 mg (þ27% change from baseline; p < 0.01) versus the 14.3 mg in the blind therapy group (þ15% change of baseline; p < 0.01) ( Table 3) .
As recommended in the study protocol, more diuretic changes occurred in patients with higher baseline PA diastolic pressure ( Figure 4) . The relationship between higher PA diastolic pressures and the number of diuretic changes was more apparent in the were observed in the blind therapy group for these therapies ( Table 3) . More vasodilator changes occurred in active monitoring patients who had higher baseline PA diastolic pressure ( Figure 5 ).
Across the range of baseline PA diastolic pressures, the frequency of vasodilator changes in the active monitoring group was 3.0 times greater than in the blind therapy group (IRR: 2.97; 95% confidence interval: 2.39 to 3.73; p < 0.0001).
The percentage of blind therapy patients given nitrates increased from 19% to 22% after 6 months, whereas nitrate therapy nearly doubled in the active monitoring group (24% to 42%; p < 0.01) ( Table 5) .
Therefore, the total daily dose of nitrate therapy was higher in the active monitoring group compared with the blind therapy patients at the end of 6 months (70.5 vs. 53.7 mg; p ¼ 0.02). Hydralazine therapy also almost doubled in the active monitoring group (13% to 23%; p < 0.01), whereas the blind therapy group had no significant change in use of this drug. Despite higher use in the active treatment group, the average HF ¼ heart failure; LVEF ¼ left ventricular ejection fraction; other abbreviations as in Table 1 .
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Pulmonary Artery Pressure-Guided Heart Failure Management daily dose of hydralazine was not different between treatment groups. Similar findings were observed in the subgroup of patients with reduced LVEF (Table 5 ).
I n c r e a s e d d o s i n g o f n e u r o h o r m o n a l a n t a g o n i s t s .
The active monitoring group experienced significant increases from baseline in doses of ACEI/ARB (þ4.23 mg; p < 0.01), BB (þ3.40 mg; p < 0.01), and AA (þ3.71 mg; p ¼ 0.03). No significant changes were observed in the blind therapy group for these therapies ( Table 3) .
There were 456 patients with a LVEF #40% at the time of enrollment. Baseline use of GDMT was excellent as shown in Table 2 . For patients on therapy
at baseline and at 6 months of follow-up (paired test), the active monitoring group patients with reduced LVEF had increases in ACEI/ARB (þ3.32 mg; p < 0.01), BB (þ3.79 mg; p < 0.01), and AA (þ4.26 mg; p ¼ 0.02).
Again, no changes in GDMT from baseline were observed in the blind therapy group ( Table 3) .
I d e n t i fi c a t i o n o f p a t i e n t s a t h i g h e r r i s k n e e d i n g d i u r e t i c c h a n g e s . Patients who were considered to require diuretic dose adjustment during the 6 months follow-up were at higher risk of events, whether PA 
TITRATION OF THERAPY. A d j u s t m e n t o f d i u r e t i c s .
Diuretics were most frequently adjusted in response to ambulatory monitoring of PA pressures, and the number of changes in the doses of these medications was closely related to PA pressure levels at baseline. This is congruent with the fact that when patients are allowed to decompensate and are hospitalized they have evidence of congestion requiring administration of intravenous diuretics to alleviate fluid overload regardless of LVEF (20) (21) (22) .
This concept also applies to the 90 days following hospital discharge in which diuretics accounted for more than 60% of all medication changes, typically in response to weight changes (23). Although Values are mean AE SD (n). *p value testing baseline dose to 6-month dose using paired Student t test within groups. Tables 1 and 2 . Values are mean AE SD (n). *p value testing treatment versus control obtained from exact Wilcoxon rank sum test.
Abbreviations as in
Abbreviation as in Table 1 . Tables 1 and 2 . 
